Summary
Eli Lilly and Company (LLY) has announced the successful completion of a significant debt offering, raising approximately $6.71 billion in net proceeds after underwriting discounts and before expenses. This capital raise involves the issuance of multiple tranches of notes, including $750 million in Floating Rate Notes due 2028 and various fixed-rate notes with maturities ranging from 2028 to 2065. The fixed-rate notes carry coupon rates from 4.000% to 5.650% per annum, while the floating-rate notes are tied to Compounded SOFR plus a spread. This substantial debt issuance is likely intended to support Eli Lilly's ongoing research and development efforts, potential acquisitions, or to strengthen its balance sheet. The diversity in note maturities and the inclusion of floating-rate notes suggest a strategic approach to managing interest rate risk and financing its long-term growth initiatives. Investors should monitor how these proceeds are deployed and their impact on the company's financial leverage and future profitability.
Key Highlights
- 1Eli Lilly & Co. successfully closed a debt offering, raising approximately $6.71 billion in net proceeds.
- 2The offering included $750 million in Floating Rate Notes due 2028, with interest tied to Compounded SOFR plus 0.530%.
- 3Several series of fixed-rate notes were issued, totaling $6 billion, with maturities ranging from 2028 to 2065.
- 4Fixed-rate notes carry annual interest rates from 4.000% to 5.650%.
- 5The issuance was registered under a Form S-3 registration statement (File No. 333-285052).
- 6The company entered into an underwriting agreement with a syndicate of major financial institutions.
- 7The notes are governed by an Indenture dated February 1, 1991, with Deutsche Bank Trust Company Americas as trustee.